Great news and with the recent key executive hires, you're going to see a lot of these initiatives that were put on the back burner start to gain traction again. Richard and Co have been stretched too thin while they focus on PromarkerD commercialisation. CCO's performance rights are designed to hit revenue and profit targets in relation to PromarkerD, which frees up the team to do what that they do best. Giddy up!
Ann: Proteomics to collaborate to validate test for endometriosis, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $60.56M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.0¢ | $21.93K | 59.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 11.52am 07/08/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |